Alpha-synuclein (α-Syn) is a key protein involved in Parkinson's disease (PD) pathology. PD
is characterized by the loss of dopaminergic neuronal cells in the substantia nigra pars …

Cell-replacement therapies have long been an attractive prospect for treating Parkinson
disease. However, the outcomes of fetal tissue-derived cell transplants in individuals with …

Clinical trials using cells derived from embryonic ventral mesencephalon have shown that
transplanted dopaminergic neurons can survive and function in the long term, as …

Parkinson disease (PD) is characterized by loss of the A9 nigral neurons that provide
dopaminergic innervation to the striatum. This discovery led to the successful instigation of …

Autologous transplantation of patient-specific induced pluripotent stem cell (iPSC)-derived
neurons is a potential clinical approach for treatment of neurological disease. Preclinical …

Midbrain dopaminergic (mDA) neuron development has been an intense area of research
during recent years. This is due in part to a growing interest in regenerative medicine and …

Degeneration of dopamine (DA) neurons in the midbrain underlies the pathogenesis of
Parkinson's disease (PD). Supplement of DA via L-DOPA alleviates motor symptoms but …

There has been an explosion in the number of papers discussing the hypothesis
of'pathogenic spread'in neurodegenerative disease—the idea that abnormal forms of …

Following intensive efforts since their discovery little more than 10 years ago, cell
replacement therapy using induced pluripotent stem (iPS) cells is now becoming reality …

Parkinson's disease (PD) is recognized by the accumulation of α-synuclein within neurons.
In contrast to the current ascending theory where α-synuclein would propagate from neuron …